Telehealth & Digital Health

A new partnership automates data flow for 2,500+ research sites, promising near-perfect accuracy and faster drug development. Here’s how it works.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

A new patented drug, budiodarone, aims to treat atrial fibrillation in heart failure patients, a group with few safe options. Is this the future of care?

A new partnership in Southern Idaho uses an AI-driven platform to offer on-demand virtual visits and fast-track screenings, tackling a national crisis in access.

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

With burnout and financial woes plaguing healthcare, Altera Digital Health bets on advanced AI to ease burdens and restore the human touch at HIMSS26.

A new program in a remote Ontario community aims to overcome systemic healthcare gaps, providing a vital blueprint for Indigenous health sovereignty.

As SAB Biotherapeutics prepares for key investor talks, a closer look reveals its novel T1D therapy and the unique bovine tech aiming to change treatment.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

With star-studded advisory board, a new biotech firm aims to turn routine dental visits into a frontline defense against oral cancer.

An 8-month-old infant weighing just 5.5 kg receives a new liver from his father in a daring surgery, marking a milestone for pediatric care in India.

The FDA has greenlit Ascendis Pharma's once-weekly YUVIWEL for achondroplasia, a major step for patients that also carries significant business implications.

Born from a Novartis mega-deal, Atrium Therapeutics aims its novel RNA platform at rare, untreatable genetic heart diseases. Will its strategy succeed?

With U.S. cancer centers tripling adoption of its targeted drug delivery device, RenovoRx signals a potential shift in treating solid tumors.

The biopharma firm beats 2025 guidance on strong specialty and generic sales, forecasting another year of growth fueled by new product launches.

With Google's Rick Osterloh on its board, Dexcom signals a major push beyond diabetes into AI-powered wellness and the consumer wearables market.

One in 10 Canadians has kidney disease, often with no symptoms. Experts urge immediate action as this silent crisis strains lives and our healthcare system.

With Phase 3 epilepsy results for its lead drug azetukalner due in March, Xenon reveals a major R&D spend and a cash runway to fuel its broad pipeline.

With millions of Canadians suffering from dry eye, a new program combines advanced tech like IPL with personalized plans to offer hope and accessible relief.

New research reveals a massive trust gap in healthcare AI as overall confidence drops. Why are users believers while the vast majority of Americans remain wary?